^
Association details:
| Biomarker: | FGFR overexpression |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | derazantinib (ARQ 087) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
541P - Derazantinib (DZB), an oral fibroblast growth factor receptor inhibitor (FGFRi), shows promising activity in PDX-tumour models with aberrations in FGFR1-3
Published date:
09/14/2020
Excerpt:
Across all models, high FGFR expression correlated significantly with efficacy (r2=0.22, p=0.001, n=46); a stronger relationship was found in LC/GC models (r2=0.42, p=0.0002, n=29).
